Paradigm Entities Hold 5.0% of UroGen Ordinary Shares

Rhea-AI Filing Summary

Paradigm BioCapital and affiliated reporting persons disclosed passive beneficial ownership of UroGen Pharma Ltd. ordinary shares. The Adviser, the Adviser GP and Senai Asefaw each report sole beneficial ownership of 2,332,066 shares, equal to 5.0% of the outstanding class, while Paradigm BioCapital International Fund Ltd. reports 2,056,187 shares or 4.4%. These percentages are calculated using 46,264,132 ordinary shares outstanding as reported by the issuer.

The statement is filed on Schedule 13G, which the reporting persons use to indicate passive holdings; the filing includes a certification that the shares were not acquired to change or influence control and disclaims beneficial ownership beyond the shares directly held. Principal business addresses and organizational jurisdictions for each reporting person are provided.

Positive

• Disclosure of a significant position: Paradigm-related reporting persons publicly disclosed 2,332,066 shares (5.0%) beneficial ownership in UroGen.
• Passive classification: The filing is a Schedule 13G, indicating the holdings are reported as passive and not intended to change control.
• Clear basis for percentages: Ownership percentages are calculated using 46,264,132 ordinary shares outstanding as reported by the issuer.

Negative

• None.

Insights

Financial Analyst

TL;DR: Paradigm disclosed a material passive stake of 5.0% in UroGen, signaling notable investor interest without intent to seek control.

The filing reports 2,332,066 shares (5.0%) held by Paradigm-related reporting persons against a base of 46,264,132 shares outstanding. As a Schedule 13G, the disclosure reflects passive ownership rather than an activist or control-seeking position. For market participants, the key takeaways are the size of the position relative to outstanding shares and the formal certification that the holdings are not for control purposes; these factors limit near-term governance implications but confirm a sizable institutional stake that could influence liquidity and investor perceptions.

Corporate Governance Expert

TL;DR: The Schedule 13G indicates passive ownership and no group formation or intent to influence issuer control was reported.

The document shows the Adviser, Adviser GP and an individual reporting person each claim sole voting and dispositive power over 2,332,066 shares, while the Fund reports 2,056,187 shares. The filing includes a certification that the securities were not acquired to change or influence control. From a governance perspective, this filing creates transparency around significant ownership but does not, by itself, trigger obligations or defenses associated with control contests; monitoring future filings remains important if positions change.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

UroGen Pharma Ltd.

(Name of Issuer)

Ordinary Shares, par value NIS 0.01 per share

(Title of Class of Securities)

M96088105

(CUSIP Number)

08/05/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. M96088105

1

Names of Reporting Persons

Paradigm BioCapital Advisors LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,332,066.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,332,066.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,332,066.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. M96088105

1

Names of Reporting Persons

Paradigm BioCapital Advisors GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,332,066.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,332,066.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,332,066.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.0 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: limited liability company

SCHEDULE 13G

CUSIP No. M96088105

1

Names of Reporting Persons

Senai Asefaw, M.D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,332,066.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,332,066.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,332,066.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. M96088105

1

Names of Reporting Persons

Paradigm BioCapital International Fund Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,056,187.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,056,187.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,056,187.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.4 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: UroGen Pharma Ltd.
(b)	Address of issuer's principal executive offices: 400 Alexander Park Drive, Princeton, NJ 08540
Item 2.
(a)	Name of person filing: This Schedule 13G is filed by the following (the "Reporting Persons"): (1) Paradigm BioCapital Advisors LP (the "Adviser"); (2) Paradigm BioCapital Advisors GP LLC (the "Adviser GP"); (3) Senai Asefaw, M.D. ("Senai Asefaw"); and (4) Paradigm BioCapital International Fund Ltd. (the "Fund"). The Fund is a private investment vehicle. The Fund and one or more separately managed accounts managed by the Adviser (the "Account") directly beneficially own the Ordinary Shares reported in this statement. The Adviser is the investment manager of the Fund and the Account. The Adviser GP is the general partner of the Adviser. Senai Asefaw is the managing member of the Adviser GP. The Adviser, the Adviser GP and Senai Asefaw may be deemed to beneficially own the Ordinary Shares directly beneficially owned by the Fund and the Account. Each Reporting Person disclaims beneficial ownership with respect to any Ordinary Shares other than the Ordinary Shares directly beneficially owned by such Reporting Person.
(b)	Address or principal business office or, if none, residence: The principal business office of the Fund is c/o Walkers, 190 Elgin Avenue, George Town, Grand Cayman KY1-9001, Cayman Islands. The principal business office of the Adviser, the Adviser GP and Senai Asefaw is 767 Third Avenue, 17th Floor, New York, NY 10017.
(c)	Citizenship: For citizenship or place of organization see Item 4 of the cover page of each Reporting Person.
(d)	Title of class of securities: Ordinary Shares, par value NIS 0.01 per share
(e)	CUSIP No.: M96088105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 on the cover page for each Reporting Person, and Item 2, which information is given as of the close of business on August 5, 2025, the Date of Event which requires the filing of this Schedule 13G.
(b)	Percent of class: See Item 11 on the cover page for each Reporting Person. The percentages of beneficial ownership contained herein are based on 46,264,132 Ordinary Shares outstanding as of July 31, 2025, as reported by the Issuer in its Form 10-Q filed with the SEC on August 7, 2025.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 on the cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Item 6 on the cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 on the cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 on the cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Paradigm BioCapital Advisors LP

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	08/12/2025

Paradigm BioCapital Advisors GP LLC

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	08/12/2025

Senai Asefaw, M.D.

Signature:	/s/ Senai Asefaw, M.D.
Name/Title:	N/A
Date:	08/12/2025

Paradigm BioCapital International Fund Ltd.

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	08/12/2025

Exhibit Information

Exhibit 99.1 - Joint Filing Agreement

FAQ

How many UroGen (URGN) shares did Paradigm disclose?

The Adviser, Adviser GP and Senai Asefaw each reported 2,332,066 shares, representing 5.0% of the class; the Fund reported 2,056,187 shares (4.4%).

Does the Schedule 13G indicate Paradigm intends to take control of UroGen (URGN)?

No. The filing is on Schedule 13G and includes a certification that the securities were not acquired to change or influence control, indicating a passive position.

What share count was used to calculate the ownership percentages for URGN?

The percentages use 46,264,132 ordinary shares outstanding as reported by the issuer.

Who are the reporting persons named in the filing for URGN?

The reporting persons are Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd.

Are voting and dispositive powers disclosed in the filing?

Yes. For the 2,332,066-share positions the filing reports sole voting power and sole dispositive power for the respective reporting persons.